The rising interest in successful weight management has spurred considerable exploration into groundbreaking treatments. Currently, Retatrutide, a combined -action GIP and glucagon-like peptide-1 (GLP-1) receptor agonist , has exhibited promising results in clinical trials, implying potential for considerable weight reduction . Consequently , sever